CGChristian G. Giske

Christian G. Giske

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian G. Giske has a total of 237 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the anti-inflammatory macrolide glasmacinal on the gut microbiota of healthy adults: an open-label trial

    by Tsegaye Sewunet, Mohammad Razavi, Kate Hanrott, Virginia Norris, Jennifer Kricker, Christian G. Giske

    Glasmacinal (EP395) is an oral macrolide, with immunomodulatory properties like antibiotic macrolides (such as azithromycin), but with negligible in vitro antimicrobial activity, which is being developed as a potential treatment to reduce exacerbations in respiratory conditions. In an open-label healthy participant trial (ClinicalTrials.gov: NCT06118684), with the primary objective of assessing potential drug-drug interactions of glasmacinal, faecal samples were collected to evaluate the impact on the gut microbiota of daily doses of glasmacinal for 2 weeks, using both phenotypic and 16S rRNA gene sequencing. Glasmacinal produced modest effects: reduced phylogenetic richness (p < 0.0001), but not evenness, and altered beta-diversity (PERMANOVA R 2 = 0.104 p.adj=0.0018 after 1 week, and R 2 = 0.059, p.adj=0.028 after 2 weeks) with reductions in Clostridiaceae , Enterobacteriaceae , and Sutterellaceae abundance. The community shift was approximately 10% after 1-week glasmacinal, and 6% after 2-weeks. With quantitative culture, only Enterobacterales was impacted. No increase or selection of resistance to azithromycin in Enterobacterales and Bacteroides , nor increase in Candida spp . or Clostridioides difficile , were detected. Overall, glasmacinal induced limited restructuring of the gut microbiome (without the defining hallmarks of antibiotic-like dysbiosis), core anaerobic phyla of the gut (Firmicutes and Bacteroidetes) were preserved, and there was no selection of antimicrobial resistance.

  • Towards a reference methodology for bacteriophage susceptibility testing – position paper of the EUCAST Phage Susceptibility Testing Subcommittee

    by Annika Y. Classen, Martha R.J. Clokie, Christian G. Giske, Ran Nir Paz, Jean-Paul Pirnay, Gregory Resch, Frédéric Laurent, Joana Azeredo, Radu Botgros, Pieter-Jan Ceyssens, et al.


  • Open Access

    β-lactamase genes in clinical isolates of Capnocytophaga canimorsus and description of a novel class D β-lactamase, OXA-1422

    by Zoja Germuskova, Eleonora Pronzini, Fanny Wegner, Tim Roloff, Tianyan Song, Miroslava Barancekova, Alois Cizek, Michael Addidle, Murray Robinson, Marc Dieu, et al.

    Capnocytophaga canimorsus (C. canimorsus) is a zoonotic pathogen transmitted by dogs and cats that can cause severe infections in humans. Antimicrobial susceptibility data remain limited, but increasing genomic evidence suggests that functional β-lactamase genes may be more widespread than previously recognized. Three C. canimorsus isolates harboring class D β-lactamase genes were selected by genomic screening from a larger collection of the Global Capnocytophaga Consortium for detailed characterization: two isolates from human clinical infections from Sweden and New Zealand, and a commensal canine isolate from the Czech Republic. We used hybrid Illumina-Nanopore genome assemblies, phylogenetic analysis, and structural modeling to characterize the genomic context and the predicted protein features of the β-lactamase genes. The functional impact of the β-lactamases on antibiotic activity was assessed by minimum inhibitory concentration (MIC) testing and confirmed through recombinant expression in the β-lactamase-negative reference strain C. canimorsus 5 (Cc5). We detected blaOXA-347 in a canine isolate and, for the first time, in a clinical C. canimorsus isolate from human infection. Additionally, we identified a previously uncharacterized allele, newly designated blaOXA-1422, in another clinical isolate. Both β-lactamases were chromosomally encoded without clear mobile genetic elements and were part of a distinct phylogenetic cluster within the OXA family. Structural modeling showed conserved class D β-lactamase architecture. Strains carrying either gene had elevated MICs for multiple β-lactams, and expression of each gene in Cc5 recapitulated these effects. The identification and phenotypic characterization of OXA-type β-lactamases in clinical C. canimorsus isolates refine our understanding of β-lactamase diversity in this species and underscore the need for systematic investigations of β‑lactamase prevalence in this zoonotic pathogen.


  • Open Access

    Conference report: The Third Bacterial Genome Sequencing Pan-European Network conference

    by Nina Liuta, Claire Bertelli, Kira Waagner Birkeland, Sofia Brunet, David Eyre, Christian G Giske, Gilbert Greub, Yukino Gütlin, Andre Kahles, Maria Lind Karlberg, et al.

    The third Bacterial Genome Sequencing Pan-European Network conference, held in Engelberg, Switzerland (12–15 January 2026), brought together experts from six European countries to discuss the implementation of bacterial genome sequencing in clinical microbiology and public health. Key themes included regulatory frameworks (In Vitro Diagnostic Regulation, General Data Protection Regulation), standardization, quality control, data sharing, economic evaluation, and the integration of artificial intelligence and long-read sequencing into diagnostic workflows. Across presentations, panel discussions, and workshops, participants emphasized that successful implementation of genome sequencing requires more than technical capacity: it depends on robust validation, sustainable funding, interoperable data standards, ethical governance, and interdisciplinary collaboration. The meeting highlighted that sequencing should remain question-driven and clinically meaningful, balancing cost, turnaround time, and public health impact. Overall, the conference reinforced the need for coordinated European efforts to advance responsible, standardized, and sustainable genomic surveillance and diagnostics.

  • Open Access

    Development of a quantitative self-assessment tool for hospital antimicrobial stewardship and infection control programs: a step towards standardizing clinical studies

    by V Zanichelli, S Z Zakariah, A Y Classen, U Dumpis, C G Giske, S Goepel, D Hagen, S B Jorgensen, J Kessel, C Kjellander, et al.

    Background: Antimicrobial stewardship (AMS) and infection prevention and control (IPC) programs are crucial for reducing antimicrobial resistance in hospitals. Existing quality indicators (QIs) for these programs are mainly qualitative, hindering external benchmarking. PILGRIM (NCT03765528) is a prospective multinational cohort study evaluating the impact of antibiotic prescription quality on intestinal domination by healthcare-associated pathogens. Objective: In this sub-study, we develop a quantitative scoring tool for AMS and IPC programs to facilitate standardized assessments of programs and support clinical studies. Methods: We used a RAND-modified Delphi consensus procedure to establish a scoring system for AMS and IPC programs. The tool was tested using data collected from eight hospitals in five countries during 2019–2024. We evaluated temporal associations between scores, Clostridioides difficile cases, hand disinfectant and antibiotic use. Results: We assessed 98 QIs, resulting in in a final set of 62 QIs (35 for AMS and 27 for IPC). For our sites, the overall median score was 29 out of 50 (IQR 28–31) for AMS and 36 out of 50 (IQR 33–38) for IPC programs. Higher-scoring sites decrease antibiotic use over time. IPC scores were positively correlated with hand disinfectant use. Conclusion: This quantitative scoring scheme represents a promising step towards standardizing assessments of AMS and IPC programs in high-income settings, enabling external comparisons and supporting future clinical studies. Further validation is needed to refine its predictive validity and ensure its utility in diverse healthcare settings.


  • Open Access

    Identifying patients at high risk for antibiotic treatment following hospital admission: a predictive score to improve antimicrobial stewardship measures

    by Moritz Beck, Carolin Koll, Uga Dumpis, Christian G. Giske, Siri Göpel, Silje Bakken Jørgensen, Johanna Kessel, Lars Kaare Kleppe, Dorthea Hagen Oma, Noa Eliakim Raz, et al.

    Purpose: Identifying patients for clinical studies evaluating strategies to reduce unnecessary antibiotic usage in hospitals is challenging. This study aimed to develop a predictive score to identify newly hospitalized patients with high likelihood of receiving antibiotics, thus improving patient inclusion in future studies focusing on antimicrobial stewardship (AMS) programs. Methods: This retrospective analysis used data from the PILGRIM study (NCT03765528), which included 1,600 patients across ten international sites. Predictive variables for antibiotic treatment during hospitalization were computed, and an additive score model was developed using logistic regression and 10-fold cross-validation. The PILGRIM score was validated in an independent cohort (validation cohort), with performance metrics assessed. Results: Data from 1,258 patients was included. In the development cohort 52.8% (n = 445) and in the validation cohort 42.4% (n = 134) of patients received antibiotics. Key predictors included hematologic malignancies, immunosuppressive medication, and past hospitalization. The logistic regression model demonstrated an area under the curve of 0.74 in the validation. The final additive score incorporated these predictors plus “planned elective surgery” achieving a specificity of 92%, a positive predictive value of 78%, a sensitivity of 41%, and a negative predictive value (NPV) of 69%in validation set. Conclusion: The PILGRIM score effectively identifies newly hospitalized patients likely to receive antibiotics, demonstrating high specificity and PPV. Its application can improve future AMS programs and trial recruitment by facilitating targeted inclusion of patients, especially in the hematological and oncological setting. Further -external and prospective- validation is needed to broaden the model’s applicability.


  • Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute

    by Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein

    Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein; Amoxicillin/clavulanate Breakpoi


  • Amoxicillin-Clavulanate Breakpoints AgainstEnterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute

    by Navaneeth Narayanan, Amy J Mathers, Eric Wenzler, Nicholas M Moore, Christian G Giske, Rodrigo E Mendes, Paul H Edelstein

    Amoxicillin-clavulanate (AMC) is among the most frequently prescribed antibiotics globally. It has broad antibacterial activity against gram-positive, gram-negative, and anaerobic bacteria, and has been utilized to treat infections caused by a broad range of pathogens. AMC breakpoints against Enterobacterales were initially set in the 1980s but since then increases in antibiotic resistance, advances in pharmacokinetic (PK)/pharmacodynamic (PD) analyses, and publication of additional clinical data prompted a reassessment by the Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing. Based on this contemporary reappraisal, the CLSI retained the Enterobacterales breakpoints but revised comments regarding dosing associated with use of the AMC breakpoints in the 2022 supplement of M100. This viewpoint provides insight into the CLSI breakpoint reevaluation process and summarizes the data and rationale used to support these revisions to the AMC Enterobacterales breakpoint.


  • Open Access

    Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial

    by Tsegaye Sewunet, Mohammad Razavi, Staffan Rosenborg, Angela Camporeale, Michael Nowak, David Melnick, Leanne B Gasink, Paul B Eckburg, Ian A Critchley, Carl Erik Nord, et al.


  • Open Access

    Performance of automated antimicrobial susceptibility testing for the detection of antimicrobial resistance in gram‐negative bacteria: a NordicAST study

    by Truls M. Leegaard, Ulrik S. Justesen, Erika Matuschek, Christian G. Giske, the NordicAST study group on automated AST

    Automated testing of antimicrobial susceptibility is common in clinical microbiology laboratories but their ability to detect low‐level resistance has been questioned. This Nordic multicentre study aimed to evaluate the performance of commercially available automated AST systems. A phenotypically well‐characterised collection of gram‐negative bacilli (Escherichia coli (n = 7), Klebsiella pneumoniae (n = 6) and Pseudomonas aeruginosa (n = 7)) with and without resistance mechanisms was examined by Danish (n = 1), Finnish (n = 6), Norwegian (n = 16) and Swedish (n = 5) laboratories. Minimum inhibitory concentrations (MICs) were determined for 12 antimicrobials with automated systems and compared with MICs obtained with gold standard broth microdilution. The automated systems used were VITEK 2 (n = 23), Phoenix (n = 4), MicroScan (n = 1), and ARIS (n = 1). Very major errors were identified for six antimicrobials; cefotaxime (6.9%), meropenem (0.4%), ciprofloxacin (0.7%), ertapenem (4.3%), amikacin (3.4%) and colistin (6.4%). Categorical agreement of MIC for the automated systems compared to broth microdilution ranged from 83% for imipenem to 100% for ampicillin and trimethoprim‐sulfamethoxazole. The analysis revealed several important antimicrobials where resistance was underestimated, potentially with significant consequences in patient treatment. The results cast doubt on the use of automated AST in the management of patients with serious infections and suggests that more work is needed to define their limitations.